Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-104 vs Stalevo in Parkinson's Disease
NCT02764125Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Apr 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of neluxicapone in Parkinson's disease (PD), sponsored by Orion Corporation. Started Apr 2016; status: completed.
02
Drugs
neluxicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02764125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764125.